Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSurya narayan patra

    Surya Narayan Patra

    Jump to

    • Bull vs Bear: What's the outlook on Sun Pharma?

      Sun Pharma is the biggest loser on the Nifty as it missed estimates. Also, the management gave a very conservative guidance of 8-10 percent growth in consolidated sales for FY17. A bullish SP Tulsian of sptulsian.com gave a support price of Rs 700.

    • No -ve observation in Sun Pharma warning note: PhillipCap

      In an interview to CNBC-TV18, Surya Narayan Patra of PhillipCapital shared his readings and outlook on Sun Pharmaceutical Industries and also spoke about the warning letter which the company has received from USFDA.

    • Have cut Dr Reddy's target price to Rs 3250/sh: Phillip Cap

      Surya Narayan Patra of Phillip Capital says that it would take minimum one year for Dr. Reddy‘s Laboratories to resolve this issue.

    • Elepsia drug more relevant to Sun Pharma: Phillipcap

      Surya Narayan Patra of Phillipcapital says the news on Elepsia is more relevant to Sun Pharma. The product was linked to one of the facilities linked to USFDA issues

    • See more upside for Biocon post Syngene listing: Phillipcap

      Biocon plans to list its research arm Syngene and on Wednesday filed prospectus with the market regulator Sebi. It aims to raise around Rs 600 crore.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347